Piper Jaffray Cuts Bristol-Myers (BMY) PT, Raises Merck's (MRK) Following BMY's CM-026 Failure
Tweet Send to a Friend
Piper Jaffray analyst Richard Purkiss lowered his price target on Neutral-rated Bristol-Myers Squibb Co. (NYSE: BMY) to $65.00 (from $69.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
